Globus Medical (GMED) Stock Overview
Develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GMED from our risk checks.
GMED Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Globus Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$80.00 |
| 52 Week High | US$101.40 |
| 52 Week Low | US$51.79 |
| Beta | 0.95 |
| 1 Month Change | 2.63% |
| 3 Month Change | -8.89% |
| 1 Year Change | 33.51% |
| 3 Year Change | 43.55% |
| 5 Year Change | 10.86% |
| Change since IPO | 492.59% |
Recent News & Updates
Seeking Alpha • Jun 03
Globus Medical: Obtaining My Backing Again
Summary Globus Medical is delivering robust organic growth and margin expansion, with Q1 sales up 27% and base revenues up 13%. Globus Medical raised full-year EPS guidance by $0.30 to $4.70–$4.80, reflecting strong operational execution and synergy realization from recent acquisitions. Shares now trade at 16–17x earnings, with net cash of $800M and operating multiples as low as 15–16x after adjusting for cash. I see current valuation and lagging sector sentiment as an attractive entry point, expecting a re-rating toward $100 as fundamentals remain strong. Read the full article on Seeking Alpha
Narrative Update • May 27
GMED: Margin Expansion And EBITDA Execution Will Drive Future Repricing Potential
Analysts have nudged their price targets on Globus Medical in a mixed but generally constructive way, with recent moves ranging from a $1 trim to a $3 lift as they weigh slightly lower growth assumptions alongside firmer margin expectations and a modestly lower forward P/E. Analyst Commentary Bullish analysts are broadly constructive on Globus Medical, pointing to a mix of valuation support and execution on profitability as key reasons for recent target tweaks and ratings actions.
Narrative Update • May 13
GMED: Future Returns Will Reflect Q4 Execution And Mid 30s Margin Path
Narrative Update The analyst fair value estimate for Globus Medical has been raised from $110.08 to $111.50, as analysts factor in Street research pointing to higher price targets following an "impressive" Q4, credible paths to mid 30s EBITDA margins, and expectations that growth in US Core Spine in 2026 could offset capital lumpiness. Analyst Commentary Recent Street research around Globus Medical centers on Q4 execution, margin progression, and how those factors feed into valuation targets.Recent updates
Seeking Alpha • Jun 03
Globus Medical: Obtaining My Backing Again
Summary Globus Medical is delivering robust organic growth and margin expansion, with Q1 sales up 27% and base revenues up 13%. Globus Medical raised full-year EPS guidance by $0.30 to $4.70–$4.80, reflecting strong operational execution and synergy realization from recent acquisitions. Shares now trade at 16–17x earnings, with net cash of $800M and operating multiples as low as 15–16x after adjusting for cash. I see current valuation and lagging sector sentiment as an attractive entry point, expecting a re-rating toward $100 as fundamentals remain strong. Read the full article on Seeking AlphaNarrative Update • May 27
GMED: Margin Expansion And EBITDA Execution Will Drive Future Repricing Potential
Analysts have nudged their price targets on Globus Medical in a mixed but generally constructive way, with recent moves ranging from a $1 trim to a $3 lift as they weigh slightly lower growth assumptions alongside firmer margin expectations and a modestly lower forward P/E. Analyst Commentary Bullish analysts are broadly constructive on Globus Medical, pointing to a mix of valuation support and execution on profitability as key reasons for recent target tweaks and ratings actions.Narrative Update • May 13
GMED: Future Returns Will Reflect Q4 Execution And Mid 30s Margin Path
Narrative Update The analyst fair value estimate for Globus Medical has been raised from $110.08 to $111.50, as analysts factor in Street research pointing to higher price targets following an "impressive" Q4, credible paths to mid 30s EBITDA margins, and expectations that growth in US Core Spine in 2026 could offset capital lumpiness. Analyst Commentary Recent Street research around Globus Medical centers on Q4 execution, margin progression, and how those factors feed into valuation targets.Narrative Update • Apr 24
GMED: Margin Progress And US Core Spine Execution Will Drive Repricing
Analysts have lifted their average price target on Globus Medical to $123, citing strong Q4 results, credible progress toward mid 30s EBITDA margins, and expectations that US Core Spine growth and improving profitability can help smooth out capital lumpiness. Analyst Commentary Bullish analysts are leaning into the recent Q4 report, raising price targets and reiterating positive views on execution, margins, and core growth drivers.Narrative Update • Apr 09
GMED: Q4 Execution And Margin Progress Will Drive Future Repricing
Narrative Update: Globus Medical The analyst price target for Globus Medical is updated to $123 from $118, as analysts point to strong Q4 execution, credible progress toward mid 30s EBITDA margins including Nevro, and expectations for continued strength in US Core Spine that they see supporting higher long term profitability and a higher future P/E assumption. Analyst Commentary Recent Street research on Globus Medical has leaned positive, with several bullish analysts updating models after the latest Q4 results and Nevro contribution.Narrative Update • Mar 26
GMED: Future Returns Will Reflect Q4 Execution And Margin Progress Potential
Analysts have nudged the fair value estimate for Globus Medical slightly higher to $110.08 from $109.54, citing a series of raised price targets in the $104 to $123 range. They attribute this to what they describe as strong Q4 results, credible EBITDA margin progress, and upside potential in both core spine and Nevro contributions.Narrative Update • Mar 10
GMED: Future Returns Will Reflect Q4 Execution And Margin Progress Potential
Our analyst price target for Globus Medical edges up to about $110 per share, supported by Street analysts highlighting stronger Q4 execution, credible progress toward mid 30s EBITDA margins including Nevro, and ongoing upside potential in US Core Spine growth and enabling technologies. Analyst Commentary Street research on Globus Medical has leaned clearly positive, with several firms lifting price targets after Q4 results and model updates that incorporate Nevro and stronger reported revenue figures.Narrative Update • Feb 24
GMED: EPS Upside And Q4 2025 Revenue Outlook Will Drive Repricing
Narrative Update on Globus Medical The analyst price target for Globus Medical has shifted from a fair value estimate of $106 to $118, as analysts factor in recent bullish ratings, raised targets following Q4 revenue preannouncements, and updated models tied to EPS upside potential. Analyst Commentary Bullish analysts have been updating their views on Globus Medical in response to recent information on revenue and earnings potential, with several research notes pointing to higher valuation frameworks supported by company specific data.
Narrative Update • Feb 09
GMED: EPS Upside And Enabling Tech Progress Will Test Execution Through 2026
Analysts have lifted their price targets on Globus Medical into a higher US$100 plus range, citing Q4 revenue preannouncements above prior Street estimates, stronger expectations for EPS, and "best quarterly revenue to date" for Enabling Technology. Together, these factors support modest tweaks to growth, margin, discount rate, and future P/E assumptions in our updated model.Narrative Update • Jan 26
GMED: Future Returns Will Reflect Q4 Execution Strength In Enabling Technology
Analysts have raised their fair value estimate for Globus Medical from US$95.70 to US$106.40, citing higher Street price targets following stronger than expected Q3 and Q4 updates, as well as revised assumptions for revenue growth and future P/E multiples. Analyst Commentary Recent research updates on Globus Medical highlight a mix of enthusiasm about execution and growth, alongside some caution around procedure trends and market exposure.Narrative Update • Jan 11
GMED: Strong Recent Execution Will Test Spine Procedure Resilience Through 2026
Analysts have raised their fair value estimate for Globus Medical to $90, up from $78.38. This change reflects higher price targets supported by stronger recent revenue updates, improved profit margin assumptions, and a slightly higher future P/E multiple in their models.Narrative Update • Dec 24
GMED: Spine Procedure Slowdown Will Pressure Long Term Earnings Outlook
Analysts have raised their fair value estimate for Globus Medical from approximately $65.00 to about $78.38 per share. This reflects confidence in the company’s solid Q3 sales and EPS beats, improved profit margin outlook, and the long term earnings contribution from the Nevro acquisition, despite expectations for moderating spine procedure growth.Narrative Update • Dec 10
GMED: Future Returns Will Reflect Execution Strength And Integration Margin Risks
Analysts have nudged their fair value estimate for Globus Medical higher, lifting the price target from approximately $91 to about $96 per share. They cite better than expected Q3 execution, a strong sales and EPS beat, and improving confidence in the company’s ability to sustain growth despite pockets of potential spine market softness.Narrative Update • Nov 26
GMED: Future Performance Will Reflect Execution Strength And Margin Headwinds Ahead
Globus Medical's analyst price target has been raised from $88.80 to $91.20 per share, as analysts cite stronger than expected operational execution, improved sales from key business segments, and robust quarterly earnings performance. Analyst Commentary The latest assessments from Wall Street reveal a complex picture for Globus Medical, shaped by recent operating performance and future market expectations.Narrative Update • Nov 11
GMED: Future Performance Will Reflect Recent Execution Amid Margin Pressures
Globus Medical's analyst price target increased by $10.62 to $88.80 per share. Analysts highlighted robust operational execution and better-than-expected contributions from recent acquisitions as key drivers for the upward revision.Narrative Update • Oct 28
Spine Procedure Trends And Robotics Will Shape Industry Position Amid Margin Pressures
Narrative Update on Globus Medical The analyst price target for Globus Medical has been reduced from approximately $80.30 to $78.18. This reflects analysts' expectations for moderating procedure growth, near-term margin pressure related to the Nevro acquisition, and tempered sales momentum in key product lines.Narrative Update • Sep 24
Aging Demographics And Robotics Will Expand Spine And Orthopedic Care
Globus Medical’s price target was revised downward as analysts cited muted year-over-year performance in the Enabling Technology segment and less-than-expected robotic sales growth, despite an EPS beat and quarter-to-quarter recovery, resulting in a new fair value of $80.30. Analyst Commentary Q2 sales were in line with the company's pre-announcement.Analysis Article • Sep 12
Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Globus Medical, Inc. ( NYSE:GMED ), is not the largest company out there, but it saw a double-digit share price rise of...Analysis Article • Jul 21
What You Can Learn From Globus Medical, Inc.'s (NYSE:GMED) P/E
Globus Medical, Inc.'s ( NYSE:GMED ) price-to-earnings (or "P/E") ratio of 41.1x might make it look like a strong sell...Seeking Alpha • Apr 23
Globus Medical: Digesting Another Acquisition
Summary Globus Medical, Inc. posted strong Q4 results and made another recent acquisition of a firm called Nevro, enhancing its product line and market position. The company has a solid balance sheet, is targeting a large market, but analyst firms are mixed on the Globus Medical's current prospects. Barclays did recently name the company as one of the mid-cap medical device stocks with low exposure to tariffs. An updated analysis around GMED stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Feb 16
Globus Medical: Some Caution After Its Deal For Nevro
Summary Globus Medical's shares rose after the NuVasive deal benefits have come through in 2024, but the easy gains seem to be over. The acquisition of loss-making Nevro has created investor discomfort, impacting near-term earnings despite potential long-term benefits. Current valuations are demanding, with shares trading at 25 times earnings, making it challenging to justify holding a position. Despite solid performance and growth prospects, I remain cautious due to high expectations and recent price volatility. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Globus Medical Stock: Re-Rated After A Solid Year
Summary Globus Medical, Inc.'s stock has surged due to a successful execution of the NuVasive deal and three consecutive guidance hikes, boosting investor confidence and valuation. The $3.1 billion acquisition of NuVasive doubled sales, with projected synergies expected to significantly enhance earnings in the coming years. Despite solid performance and improved guidance, the stock's re-rating to $81 suggests that easy money has been made, prompting profit-taking. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Globus Medical: A Post Acquisition Analysis
Summary The shares of Globus Medical, Inc. have rebounded after concerns over its acquisition of Nuvasive last year and have gained 40% since early May. The company is getting a one-time massive surge in sales because of this merger, which should bolster international growth opportunities and round out its product portfolio. Can the rally in the shares continue? An updated analysis of Globus Medical follows in the paragraphs below. Read the full article on Seeking Alpha
New Narrative • Aug 25
Calculated Initiatives And Innovative Technologies Propel Growth In Medical Equipment Sector
Strategic integration and new product launches aim to increase Globus Medical's market share and future revenue through enhanced offerings.Shareholder Returns
| GMED | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.3% | 2.1% | -2.8% |
| 1Y | 33.5% | -20.9% | 22.8% |
Return vs Industry: GMED exceeded the US Medical Equipment industry which returned -20.9% over the past year.
Return vs Market: GMED exceeded the US Market which returned 23.5% over the past year.
Price Volatility
| GMED volatility | |
|---|---|
| GMED Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GMED has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GMED's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 6,000 | Keith Pfeil | www.globusmedical.com |
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems.
Globus Medical, Inc. Fundamentals Summary
| GMED fundamental statistics | |
|---|---|
| Market cap | US$10.86b |
| Earnings (TTM) | US$586.71m |
| Revenue (TTM) | US$3.10b |
18.5x
P/E Ratio3.5x
P/S RatioIs GMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMED income statement (TTM) | |
|---|---|
| Revenue | US$3.10b |
| Cost of Revenue | US$977.07m |
| Gross Profit | US$2.12b |
| Other Expenses | US$1.54b |
| Earnings | US$586.71m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.32 |
| Gross Margin | 68.49% |
| Net Profit Margin | 18.92% |
| Debt/Equity Ratio | 0% |
How did GMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 06:45 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Globus Medical, Inc. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |